JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Fulgent Genetics Inc

Затворен

СекторЗдравеопазване

22.7 -2.7

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.39

Максимум

23.33

Ключови измерители

By Trading Economics

Приходи

-7.4M

-19M

Продажби

8.3M

82M

Марж на печалбата

-23.539

Служители

1,313

EBITDA

-3.5M

-15M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+8.11% upside

Дивиденти

By Dow Jones

Следващи печалби

7.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

165M

713M

Предишно отваряне

25.4

Предишно затваряне

22.7

Настроения в новините

By Acuity

72%

28%

336 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Fulgent Genetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.10.2025 г., 23:50 ч. UTC

Горещи акции

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28.10.2025 г., 23:25 ч. UTC

Печалби

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28.10.2025 г., 23:18 ч. UTC

Печалби

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28.10.2025 г., 22:20 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28.10.2025 г., 22:13 ч. UTC

Печалби

Wal-Mart de Mexico Net Profit Falls in 3Q

28.10.2025 г., 21:38 ч. UTC

Печалби

Correction to Visa Sales Jump Article

28.10.2025 г., 21:17 ч. UTC

Печалби

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28.10.2025 г., 21:07 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- Update

28.10.2025 г., 21:02 ч. UTC

Печалби

Mondelez Tempers Outlook as Costs Rise

28.10.2025 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28.10.2025 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28.10.2025 г., 23:02 ч. UTC

Печалби

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28.10.2025 г., 23:01 ч. UTC

Печалби

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28.10.2025 г., 22:46 ч. UTC

Печалби

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28.10.2025 г., 22:45 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.6T >000660.SE

28.10.2025 г., 22:44 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.44T >000660.SE

28.10.2025 г., 22:43 ч. UTC

Печалби

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28.10.2025 г., 22:42 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28.10.2025 г., 22:20 ч. UTC

Печалби

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28.10.2025 г., 22:02 ч. UTC

Печалби

Review & Preview: Earnings Extravaganza -- Barrons.com

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене
Печалби

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28.10.2025 г., 21:20 ч. UTC

Печалби

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28.10.2025 г., 21:19 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28.10.2025 г., 21:18 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Сравнение с други в отрасъла

Ценова промяна

Fulgent Genetics Inc Прогноза

Ценова цел

By TipRanks

8.11% нагоре

12-месечна прогноза

Среден 25.33 USD  8.11%

Висок 30 USD

Нисък 21 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Fulgent Genetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

2

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

17.32 / 19.04Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

336 / 373 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat